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Abstract
We used digital long serial analysis of gene expression to discover gene expression differences between node-
negative and node-positive colorectal tumors and developed a multigene classifier able to discriminate between
these two tumor types. We prepared and sequenced long serial analysis of gene expression libraries from one
node-negative and one node-positive colorectal tumor, sequenced to a depth of 26,060 unique tags, and identified
262 tags significantly differentially expressed between these two tumors (P < 2 × 10−6). We confirmed the tag-to-
gene assignments and differential expression of 31 genes by quantitative real-time polymerase chain reaction, 12
of which were elevated in the node-positive tumor. We analyzed the expression levels of these 12 upregulated
genes in a validation panel of 23 additional tumors and developed an optimized seven-gene logistic regression
classifier. The classifier discriminated between node-negative and node-positive tumors with 86% sensitivity
and 80% specificity. Receiver operating characteristic analysis of the classifier revealed an area under the curve
of 0.86. Experimental manipulation of the function of one classification gene, Fibronectin, caused profound effects
on invasion and migration of colorectal cancer cells in vitro. These results suggest that the development of node-
positive colorectal cancer occurs in part through elevated epithelial FN1 expression and suggest novel strategies
for the diagnosis and treatment of advanced disease.
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Introduction
Colorectal cancer is the third leading cause of cancer deaths in the
United States. It is estimated that 149,000 individuals will have their
conditions diagnosed with colorectal cancer during 2008 and that
50,000 deaths will result from this disease. Diagnosis before spread
to the regional lymph nodes (node-negative disease) is associated
with a 90% 5-year survival rate, whereas diagnosis after lymphatic
spread (node-positive disease) decreases survival to a 67% 5-year rate
[1]. The diagnosis of node-positive disease is accomplished by histologic
examination of regional lymph nodes available within the surgically
excised tissue. The probability of disease-free survival of patients diag-
nosed with node-negative disease increases with the number of negative
nodes observed [2]. The mechanism by which node sampling is related
to outcome is not clear, but one possibility is that a portion of node-
negative individuals is understaged because of insufficient sampling
depth. Current guidelines recommend that colorectal cancer patients
have a minimum of 12 lymph nodes examined; however, only 37%
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of patients receive the proper level of lymph node evaluation [3]. De-
spite careful attention to node status at the time of surgery, a significant
number of node-negative patients experience a recurrence of their
disease within 5 years and may have been understaged. A molecular test
that identifies node-positive colorectal cancer would therefore be of
substantial clinical value.
To identify gene expression markers of lymph node involvement,
expression profiling of colorectal cancers has been performed and
genes associated with node status were reported [4–6]. In addition,
gene expression profiling has been used to identify markers associated
with node status in other epithelial neoplasms such as pancreatic can-
cer [7], oral squamous cell carcinoma [8], and invasive breast cancer
[9]; however, the mechanisms by which these marker genes influence
pathology remain to be elucidated.
We applied high-throughput pyrosequencing to long serial analysis
of gene expression (SAGE) to obtain deep expression profiles of
lymph node–negative and lymph node–positive human colorectal
cancers. From this, we observed 262 tags that were significantly dif-
ferentially expressed and confirmed the tag-to-gene assignments of
30 genes with altered expression between these two tumor types.
In particular, we found that node-negative tumor epithelial cells ex-
press low levels of FN1 messenger mRNA (mRNA) and protein,
whereas node-positive tumor epithelial cells express high levels of
FN1 mRNA and protein. We subsequently demonstrated that forced
overexpression of FN1 dramatically increased the migratory and in-
vasive properties of SW480 colorectal cancer cells. These results in-
dicate that elevated epithelial FN1 expression in primary colorectal
cancers may be a useful molecular marker of positive lymph node
status and suggest that fibronectin-integrin antagonists may be useful
additions to standard chemotherapy treatments for node-positive
colorectal cancer patients.
Materials and Methods
Tumor Specimens and Laser Capture Microdissection
Twenty-five primary colorectal cancers were collected at the time
of surgery by the South Carolina Biorepository System and imme-
diately frozen at −80°C. Tissue samples were embedded in frozen-
section medium (RA Scientific, Kalamazoo, MI), cut into 25 × 20-μm
sections, and fixed onto silane-prep glass slides (Sigma, St Louis,
MO) by sequential dehydration in baths of 75%, 95%, and 100%
ethanol followed by xylene. Slides were air-dried and desiccated be-
fore laser capture microdissection. Guide slides were cut and stained
with hematoxylin and eosin to aid in the identification of epithelial
cells during laser capture dissection of unstained sections. Tumor
epithelial cells were captured onto CapSure Macro LCM Caps (Mo-
lecular Devices, Sunnyvale, CA) using an ArcturusPixCellIIe laser
capture microdissector. Caps containing excised cells were imme-
diately placed onto 0.5-ml Eppendorf tubes containing 200 μl of
lysis/binding buffer (Invitrogen, Carlsbad, CA) up to five aliquots
of lysis buffer were sequentially used to lyse five caps each to create
a total lysate of approximately 1 ml.
Genomic DNA Purification, Quantification, and Mismatch
Repair Proficiency Testing
Genomic DNA was purified from microdissected epithelial cell
lysates using QIAamp DNA Micro Kit (Qiagen, Valencia, CA).
DNA was quantitated using real-time polymerase chain reaction
(PCR) primers directed against long interspersed nuclear element
sequences (LINEF-AAAGCCGCTCAACTACATGG, LINER-
CTCTATTTCCTTCAGTTCTGCTC; Integrated DNA Tech-
nologies, Coralville, IA). PCR was performed using 6.25 μl of
iTaqSupermix (Bio-Rad, Hercules, CA), 1.25 μl of 2 μM LINEF,
1.25 μl of 2 μM LINER, 2.5 μl of PCR water (Invitrogen), and
1.25 μl of DNA template. Thermal cycling was performed using a
MyIQ Thermal Cycler (Bio-Rad) and the following protocol: 1 cycle
at 95°C for 1 minute, 60 cycles at 94°C for 10 seconds and at 59°C
for 30 seconds, and 1 cycle at 70°C for 5 minutes.
Mismatch repair–proficient and –deficient tumors were identified
by assessing the stability of the BAT26 microsatellite locus in each
tumor. BAT26 microsatellite PCR products were prepared using
6.25 μl of iTaqSupermix (Bio-Rad), 1.25 μl of 2 μM BAT26F
(TGACTACTTTTGACTTCAGCC), 1.25 μl of 2 μM BAT26R
(AACCATTCAACATTTTTAACCC), 2.5 μl of PCR water (Invitro-
gen), and 1.25 μl of DNA template. Thermal cycling was performed
MyIQ Thermal Cycler (Bio-Rad) using the following protocol: 1 cycle
at 95°C for 1 minute, 60 cycles at 94°C for 10 seconds and at 59°C
for 45 seconds, and 1 cycle at 68°C for 5 minutes. PCR products were
analyzed by electrophoresis on a 3% agarose gel and photographed
using an Alpha Imager and Quantity One software (Alpha Innotech,
San Leandro, CA). Only microsatellite stable tumors were used for
gene expression studies.
Messenger RNA Purification and Complementary
DNA Synthesis
Messenger RNA was isolated from microdissected epithelial cells
using mRNA direct beads from the I-SAGE Long Kit (Invitrogen) ac-
cording to the manufacturer’s instructions. Complementary DNA
(cDNA) was prepared by reverse transcription in a 90-μl reaction vol-
ume containing 18 μl of 5× first-strand buffer, 1 μl of RNAse OUT,
54.5 μl of diethylpyrocarbonate water, 9 μl of 0.1 M DTT, 4.5 μl
of 10 mM deoxyribonucleotide triphosphate mix, and 3 μl of Super-
script II Reverse Transcriptase (Invitrogen) incubated at a temperature
of 42°C for 1 hour. Quantity and quality of the resulting cDNA were
determined for each sample by quantitative real-time PCR against
the 5′ and 3′ portions of the EEF1A1 transcript. Quantitative real-
time PCR was performed using 12.5 μl of iTaqSupermix (Bio-Rad),
2.5 μl of 2 μM forward primer, 2.5 μl of 2 μM reverse primer, and
6.5 μl of nuclease-free water per reaction. Thermal cycling was per-
formed using a MyIQ Thermal Cycler (Bio-Rad) and the follow-
ing protocol: 1 cycle at 95°C for 1 minute and 50 cycles at 94°C
for 10 seconds and at 60°C for 30 seconds. A standard curve was
created from 5 μg of normal colon cDNA (Clontech, Palo Alto,
CA) diluted serially at 1:4 for a total of five standards. Quantity was
determined by the concentration of EEF1A1 as reported from the
standard curve using MyIQ software version 1.0 (Bio-Rad). The reac-
tions were performed in triplicate, and the concentrations were aver-
aged. mRNA quality was determined by comparing the ratios of the
quantities of 5′ and 3′ segments of the control EEF1A1 transcript, and
samples of sufficient quality (5′EEF1A1/3′EEF1A1) greater than 0.5
were used for second-strand cDNA synthesis, RNA amplification,
and SAGE library construction.
Second-strand cDNA synthesis was performed by adding 465 μl of
diethylpyrocarbonate water, 150 μl of 5× second-strand buffer, 15 μl
of deoxyribonucleotide triphosphate mix, 5 μl of Escherichia coli DNA
ligase, 20 μl of E. coli DNA polymerase, and 5 μl of E. coli RNase H
(Invitrogen) to the first-strand cDNA synthesis reactions. The re-
action mixture was incubated at 16°C for 2 hours. The solid-phase
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double-stranded cDNA was washed and digested in a reaction mix-
ture containing 172 μl of 3 mM Tris-HCl, 0.3 mM EDTA, pH 8.0;
2 μl of 100× BSA; 20 μl of 10× buffer 4; and 6 μl of NlaIII en-
zyme (Invitrogen).
T7 RNA Transcription/RNA Amplification
To amplify the 3′ ends of mRNA for SAGE, we prepared a linker
containing the T7 RNA polymerase promoter sequence and ligated this
linker to NlaIII-digested double-stranded cDNA. Forty nanograms of
T7 LongSAGE adapter (T7 FWD: 5′-CAGAGAATGCATAATACG-
TACTCACTATAGGGATCCACAAGAACTACTACATG-3′; and
T7 REV: 5′PO4TAGTAGTTCTTGTGGATCCCTATAGTGAGT-
CGTATTATGCATTCTCTG-3′) was ligated to bead-bound NlaIII-
digested double-stranded cDNA in a reaction containing 14.5 μl of
3 Mm Tris-HCl, 0.3 mM EDTA, pH 8.0; 1 μl of T7 adapter; 2 μl
of 10× ligase buffer; and 2.5 μl of T4 DNA ligase (Invitrogen). Excess
adapter was removed by washing the bead-bound double-stranded
cDNA three times with wash buffer D (Invitrogen). RNA was ampli-
fied using the T7 MEGAscript kit (Ambion, Austin, TX) in a reaction
containing 2 μl of adenosine 5′-triphosphate solution, 2 μl of cytidine
5′-triphosphate solution, 2 μl of guanosine 5′-triphosphate solution, 2 μl
of uridine 5′-triphosphate solution, 2 μl of 10× reaction buffer, 2 μl of
enzyme mix, and 8 μl of nuclease-free water. The reaction mixture was
incubated at 37°C overnight. Amplified RNA generated by the in vitro
transcription reaction was eluted from the beads using 40 μl of nuclease-
free water at 70°C for 5 minutes.
LongSAGE
One-tenth of the total transcribed RNA containing supernatant was
reverse-transcribed and quantified by real-time PCR. An aliquot equiv-
alent of 20 μg of total RNA was used from the remaining supernatant
as an input for the I-SAGE Long Kit. LongSAGE libraries were created
using the manufacturer’s instructions with the following alterations:
Primers used for DiTAG amplification were modified to contain a se-
quencing site for recognition by 454 Life Sciences (Branford, CT). The
primer sequences used were 454LongSAGEA2 5′-GCC TCC CTC
GCG CCA TCA GTT GGA TTT GCT GGT GCA GTA-3′ and
454LongSAGEB1 5′-GCC TTG CCA GCC CGC TCA GCG AAT
TCA AGCTTCTAACGATG-3′. The resulting DiTAGs were directly
sequenced on aGS20without concatamerization or cloning into bacteria.
Real-time PCR
Quantitative real-time PCR was used to quantify FN1, PITX2,
FLJ22104, RPL39, EIF1AX, AP3S1, NDUFA8, and EEF1A1 expres-
sion using the following primers:
FN1 FWD 5′-TGG CCAGTCCTACAACCAGT-3′;
FN1 REV 5′-CGGGAATCTTCTCTGTCAGC-3′;
PITX2 FWD 5′-ATGGAGACCAACTGCCGCAA-3′;
PITX2 REV 5′-TCACACGGGCCGGTCCACTGC-3′;
FLJ22104 FWD 5′-GCAGCTGTCATGGAAGTTCA-3′;
FLJ22104 REV 5′-CATCAAGGACTTTTCGGTTCA-3′;
RPL39 FWD 5′-CTCGCCATGTCTTCTCACAA-3′;
RPL39 REV 5′-CCAGCTTGGTTCTTCTCCAA-3′;
EIF1AX FWD 5′-GCAGTGTACTGGAGAGGGGA-3′;
EIF1AX REV 5′-TGAAGCTGAGACAAGCAGGA-3′;
AP3S1 FWD 5′-TGATGCACAAAATAAGCTGGA-3′;
AP3S1 REV 5′-TTGGGATCTCAGGAAGATTCA-3′;
NDUFA8 FWD 5′-GTGTGTGCTGGACAAACTGG-3′;
NDUFA8 REV 5′-GGGATTCTCCGGTAAAGGTC-3′;
EEF1A1 FWD 5′-CAATGCTTCCACCAACTCGT-3′;
EEF1A1 REV 5′-TCTTGACATTGAAGCCCA-3′.
PCR was performed using 12.5 μl of iTaqSupermix (Bio-Rad),
2.5 μl of 2 μM forward primer, 2.5 μl of 2 μM reverse primer,
and 6.5 μl of nuclease-free water per reaction. Thermal cycling
was performed using a MyIQ Thermal Cycler (Bio-Rad) and the fol-
lowing protocol: 1 cycle at 95°C for 1 minute and 50 cycles at 94°C
for 10 seconds and at 60°C for 30 seconds. Gene expression levels
were standardized to cDNA concentration by computing the differ-
ence between the cycle threshold (C t) value of each classifier gene
and the cycle threshold (C t) value for a control gene (EEF1A1).
Logistic Regression Classifier
Denote the standardized expression levels of FN1, FLJ22104,
RPL39, PITX2, EIF1AX, AP3S1, and NDUFA8 by X1 to X7
as shown.
Denote the gene expression level vector by X = (X1, …, X7). Let Y
be the node status variable: Y = 1 means node-positive and Y = 0
node-negative. The logistic regression (LR) model specifies the prob-
ability that a colorectal tumor is node-positive as a function of gene
expression levels given by the following:
P Y = 1jX = xð Þ = exp β0 + β1x1 + … + β7x7f g
1 + exp β0 + β1x1 + … + β7x7f g
Given the gene expression level vector and the node status of n =
23 tumors, denoted by (yi, xi), i = 1, 2, …, 23, the maximum like-
lihood estimates of the LR coefficients β0, β1, …, β7, denoted by b0,
b1, …, b7, can be obtained through iterative procedures that are im-
plemented in theR statistical package [10], the package that we used [11].
Given a new tumor with unobserved node status Y * and an ob-
served gene expression level vector X * = x*, we estimate the proba-
bility that the tumor is node-positive through
Pˆ Y * = 1jX * = x*ð Þ = exp b0 + b1x*1 + … + b7x*7f g
1 + exp b0 + b1x*1 + … + b7x*7f g
The LR classifier is of the form
δcðx*Þ = 1 if PˆðY * = 1jX * = x*Þ ≥ c0 if PˆðY * = 1jX * = x*Þ < c

ð1Þ
where c is between 0 and 1, a properly chosen cutoff or threshold.
This means that if the estimated probability of node-positive status is
at least c, we classify the tumor as node-positive.
Predictor Description
X1 FN1-EEF1A1
X2 FLJ22104-EEF1A1
X3 RPL39-EEF1A1
X4 PITX2-EEF1A1
X5 EIF1AX-EEF1A1
X6 AP3S1-EEF1A1
X7 NDUFA8-EEF1A1
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If we denote a gene expression vector
V = b1x*1 + … + b7x*7
then the estimated probability that the tumor is node-positive is
given by
Pˆ Y * = 1jX * = x*ð Þ = exp b0 + Vf g
1 + exp b0 + Vf g
The LR classifier becomes
δcðx*Þ = 1 if V ≥ d0 if V < d

ð2Þ
The cutoff or threshold d is related to the original cutoff c through
d = log
c
1 − c
 
− b0
Usually, the cutoff c would be chosen to be 0.5, but the determi-
nation of the appropriate cutoff for the LR classifier is tied in to the
desired performance of the classifier. We assessed the performance of
the classifier with regards to its false-positive rate (FPR) and its false-
negative rate (FNR) by constructing and evaluating a receiver oper-
ating characteristic (ROC) curve.
For a given tumor with node status Y0 and gene expression level
vector X0, the conditional FPR associated with the LR classifier with
cutoff c is defined as the probability that it is classified to be node-
positive given that it is actually node-negative, whereas the conditional
FNR is defined as the probability that it is classified to be node-
negative given that it is actually node-positive. Taking averages of these
quantities with respect to the distribution of (Y0, X0), we obtain the
FPR and FNR, respectively, each of which is a function of the cutoff
value c. The ROC curve is defined as the graph of FPR(c) versus 1 −
FNR(c), where c ranges from 0 to 1. Or equivalently, it is the graph of
the false-positive fraction versus the true-positive fraction at different
cutoff values of c. The area under this curve is called the AUROC
and serves as a measure of the quality of the class of classifiers.
Observe that from the definitions of the FPR and the FNR, the
appropriate way to estimate FPR and FNR is to evaluate indepen-
dent test data that are different from the training data used to gen-
erate the classifier. However, our sample data set is small and we did
not have an independent test data set from which to measure the
FPR and FNR functions. We therefore used the training data (Yi,
Xi), i = 1, 2, …, 23, to estimate FPR(c) by FP^R(c), which is the ob-
served proportion of false-positives, whereas estimate FNR(c) by
FNˆR(c), which is the observed proportion of false-negatives. The
empirical ROC curve is then given by the graph of FP^R(c) versus
1 − FNˆR(c) (or the observed false-positive fraction versus the observed
true-positive fraction), and the empirical AUROC is given by the area
under the empirical ROC curve.
We determined the appropriate value of the cutoff c (denoted as
c*) from the empirical ROC by imposing an upper limit on the value
of the FPR and to subsequently minimize the FNR. The approach
adopted here is from clinical considerations that lead us to expect up
to 20% false-positives (because of misdiagnosed node-negative dis-
ease), hence the need to control the FPR at the outset through the
specification of the FPR threshold.
On determination of c* through the previously mentioned ap-
proach, the final LR classifier becomes δc*(x*) as given in (1) with
c replaced with c*. Or, in the alternative form in (2), we use in this
case the cutoff value of d* = log(c* / (1 − c*)) − b0 for d.
Fibronectin Immunofluorescence Microscopy
Frozen tumor specimens were cut into 10-μm sections and fixed
onto silane-prep slides (Sigma). Sections were fixed in 95% ethanol,
washed with PBS, and blocked with normal goat serum (Biogenex,
San Ramon, CA) for 1 hour at room temperature. Samples were
probed with either a 1:200 dilution of rabbit antifibronectin primary
or a 1:500 dilution of mouse anti-BerEP4 primary antibody for 1 hour
at room temperature. Samples were washed with PBS and then in-
cubated with a 1:500 dilution of the appropriate AlexaFluor 488–
conjugated secondary (Invitrogen). Samples were washed in PBS and
coverslipped using 4′,6-diamidino-2-phenylindole, dihydrochloride–
containing mounting medium.
Fibronectin Western Blot Analysis
Cell lysates from SW480 colorectal cancer cells and FN1-transfected
subclones were lysed directly in Laemmli sample buffer. Cell num-
bers were quantitated by purifying genomic DNA and performing
LINE PCR as described. Equivalent cell numbers were electrophoresed
on 8% SDS–polyacrylamide gel and transferred electrophoretically
to a polyvinylidine fluoride membrane at 80 mA overnight. Blots
were probed with polyclonal rabbit anti-FN1 primary antibody over-
night at 4°C (1:1000 dilution in 5% milk; part no. F3468; Sigma)
or monoclonal mouse antitubulin antibody (1:20,000 dilution in 5%
milk; part no. T9026; Sigma) for 1 hour at room temperature. Blots
were washed and then probed with HRP-conjugated goat antirabbit
immunoglobulin G secondary antibody (1:10,000 diluted in 5% milk;
part no. PI-1000; Vector Laboratories, Burlingame, CA) for 2.5 hours at
room temperature or HRP-conjugated goat antimouse secondary anti-
body (1:20,000 diluted in 5% milk) for 1 hour at room temperature.
Bands were imaged by incubating the blots in ECLWestern Blotting De-
tecting Kit (RPN21061; GE Healthcare Bio-Sciences, Piscataway, NJ)
and exposing to x-ray film (Kodak Biomax XAR Film part no. 05-
728-41; Thermo Fisher Scientific, Waltham, MA) for 5 minutes.
Cell Culture Methods
SW480 cells were a kind gift from Dr. Marj Peña. The cells were
maintained in McCoy’s 5A medium (Invitrogen) supplemented with
1× penicillin/streptomycin (Gibco, Carlsbad, CA) and 10% fetal bo-
vine serum (Invitrogen) in a humidified incubator with 5% CO2.
Generation of FN-Expressing Clones
A full-length cDNA encoding adult Fibronectin (FN1) was cloned
into the pIRES-Neo3 vector (Clontech,MountainView, CA) and trans-
fected into SW480 cells using Lipofectamine (Invitrogen). Single clones
were selected by limiting dilution and growth using 1000 μg/ml G418.
Clones were tested for FN1 mRNA expression by real-time PCR.
Migration and Invasion Assays
Invasion assays were performed using BD BioCoat Matrigel Invasion
Chambers (BD Biosciences, San Jose, CA) according to the manufac-
turer’s instructions. Either 50,000 cells (migration) or 100,000 cells
(invasion) were seeded into the top of empty transwell migration cham-
bers (migration) or chambers containingMatrigel inserts (invasion) and
placed into culture wells containing complete medium with 10% fetal
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bovine serum as a chemoattractant. Assays were performed in the ab-
sence or presence of 4.5 μM of an inhibitory cyclic RGDfV peptide
[12,13]. Cells were allowed to migrate or invade for 3 days, after which
the filters were removed, stained with crystal violet, and visualized by
microscopy. Cell counts were performed in triplicate and averaged.
Results
To identify genes that are differentially expressed during the progres-
sion of colorectal cancer, we modified the LongSAGE tags for amplicon
sequencing on a 454 GS20 genome sequencer (454 Life Sciences). We
laser capture microdissected tumor epithelial cells, purified and ampli-
fied mRNA, and prepared LongSAGE libraries from one node-negative
and one node-positive colorectal tumor. Specific tumors were chosen
based on the quantity and quality of mRNA recovered. LongSAGE
tags were modified for 454 sequencing as described. One sequencing
run on the 454 GS20 platform produced 351,943 sequencing reads
from which 327,294 total tags were extracted, 26,060 of which were
unique and expressed two or more times (Table 1A). One hundred fifty
tags were differentially expressed by at least 25-fold (Table 1B). To con-
trol against contaminant inflation of type I error from multiple testing,
we used a Bonferroni correction to arrive at a cutoff value of 0.05/
26,060 = 1.9 × 10−6 for the P values for each pairwise comparison
[14]. Under this conservative approach, 262 tags were defined to be
statistically significantly differentially expressed between node-negative
and node-positive colorectal tumors (Figure 1).
To validate the tag-to-gene assignments and eliminate potential bias
introduced during RNA amplification, we analyzed the best gene
matches for the top 75 most differentially expressed tags (binomial
P < 2 × 10−6, ratio >20) in unamplified cDNA from the profiled tumors
using quantitative real-time PCR. From this analysis, we confirmed the
tag-to-gene assignments and differential expression of 30 genes. The
expression ratios observed by real-time PCR were in good agreement
with the expression ratios observed by SAGE (Figure 2 and Table 2).
We then analyzed the expression of the 12 genes that were in-
creased in node-positive colorectal cancer in a panel of 23 addi-
tional colorectal tumors (Table W1). Using an LR approach, we
developed a seven-gene classifier, as described in the Materials and
Methods section, capable of discriminating between node-negative
and node-positive tumors (Figures 3, A–D, W1, A–E ). In this set
of tumors, the probability that an individual colorectal cancer was
node-positive could be estimated using a function of the seven-gene
expression values relative to the control gene, EEF1A1. For each tu-
mor, we compute a composite gene expression value, V, according to
the normalized cycle threshold (C t) values observed for the seven best
genes through the formula
V = − 0:39 × FN1Ct − EEF1A1Ctð Þ
− 0:14 × FLJ22104Ct − EEF1A1Ctð Þ
− 0:84 × RPL39Ct − EEF1A1Ctð Þ
+ 0:12 × PITX2Ct − EEF1A1Ctð Þ
+ 0:26 × EIF1AXCt − EEF1A1Ctð Þ
+ 0:25 × AP3S1Ct − EEF1A1Ctð Þ
+ 0:26 × NDUFA8Ct − EEF1A1Ctð Þ
Figure 1. Distribution of SAGE tags. Tag counts of zero were converted to 0.5 to plot on log scale and to compute expression ratios.
Significantly differentially expressed tags (binomial P < 2 × 10−6) are shown as triangles.
Table 1. Summary of LongSAGE Data.
(A)
Library Total Reads Total Tags
18964 node− 162,576 170,372
29271 node+ 189,367 195,452
Combined 351,943 365,824
(B)
Fold Differential
Expression
No. of Tags Elevated
in Node-Positive
No. of Tags Elevated
in Node-Negative
50 12 22
25 76 74
10 644 505
5 3876 2659
Tumor no. 18964 (node-negative) and tumor no. 29271 (node-positive) were sequenced to a
depth of 365,824 total tags. To minimize sequencing errors, only tags that were observed two
or more times were counted.
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The estimated probability of metastatic disease is then given by
P =
expf − 0:99 + V g
1 + expf − 0:99 + V g
As described in the Materials and Methods section, based on this
value of P, a classifier could be developed, which is of the form where
a tumor is classified as node-positive whenever the estimated proba-
bility P is greater than or equal to the cutoff value c. We evaluated the
sensitivity and specificity of this class of LR classifiers at different
cutoff values c and formed the empirical ROC curve. Because the
recurrence rate from node-negative colorectal cancer can approach
20% [15], we set this value as an upper limit for the number of
truly node-positive tumors that were inappropriately given a node-
negative diagnosis. We therefore imposed the constraint that the
estimated FPR (node-negative colon cancers receiving a positive gene
expression score) should be no more than 20%, which corresponds
to 80% specificity. This led to an optimal cutoff value of c =
0.43, and the resulting LR classifier has a sensitivity of 86%. ROC
analysis of the class of LR classifiers revealed an area under the curve
of 0.86 (Figure 3D). The selected LR classifier with cutoff of c =
0.43 correctly identified 21 of 25 tumors. The classifier performs
significantly better than a random classifier (binomial P = .00046).
Interestingly, one node-negative tumor (15095) scored very high
on the LR classifier scale (with an estimated probability of being
node-positive of 0.85), suggesting that this individual was misdi-
agnosed, harbors occult node-positive disease, and is at high risk
for recurrence.
Because of its role in normal cell adhesion and its association with
melanoma metastasis [16], we focused our attention on the Fibro-
nectin gene (FN1), which was upregulated more than 20-fold
in the node-positive LongSAGE library. To determine if the fi-
bronectin protein is also upregulated in node-positive tumors, we
performed immunofluorescence microscopy on node-positive and
node-negative colorectal tumors. Samples were triple labeled with
anti-FN1, anti-BerEP4 epithelial marker, and a DAPI nuclear stain.
As previously reported [17], we observed dramatic expression of
fibronectin protein in the stromal fibroblasts of normal colon and
both node-negative and node-positive colon cancers. In addition,
Figure 2. Confirmed differentially expressed genes. Expression levels were determined by quantitative real-time PCR, and the ratio of
node-positive to node-negative gene expression levels is plotted versus the ratio of node-positive to node-negative tag counts.
Table 2. Differentially Expressed LongSAGE Tags and Corresponding Tag-to-Gene Matches.
SAGE Tag Gene Symbol SAGE N(+)/N(−) Real-time PCR
N(+)/N(−)
TGTACCTCAGCTTTTTC ORM2 102.00 1002.93
ATTTTTACTAATGTATT UBD 84.00 28.25
AAAACATTATGACTTTT AP3S1 50.00 15.51
AATTAACTCCGTTAAAA ALDH1B1 42.00 2.53
CGGTTTGCATCGACTGA NDUFA8 38.00 1.66
CCACTGCACTCCAGCAG FLJ22104 32.00 54.57
TGTCAGAATTTCATTCC CTPS2 32.00 4.69
GCGAGCAGCGGAGTCAA RPL39 30.00 8.51
ACAGCTAATTAGTACTA EIF1AX 28.00 11.88
AGAATCACTTGAACCCA HRH1 27.50 22.32
ATCTTGTTACTGTGATA FN1 23.00 20.66
GGAGTAAAATATACTGC PITX2 18.00 9.51
CGTGCGAGACACGTGTG C1orf30 0.05 0.00
GTAGCGCCTCCTAACAG CST7 0.04 0.03
TTGATGGGCGACTTCAA DNASE1 0.04 0.04
GGTACCCATTTGATAAG DUSP6 0.04 0.19
ACAAGATATTTCTACCT CASP4 0.04 0.22
GACCAGTGGCTGGTCTC GPA33 0.04 0.01
GGTATTAACCACAGATT DEFA6 0.03 0.05
AACAGCAAGGAGTGTTT APCDD1 0.03 0.16
GCCAAGGAGTTCCAGGA GPR35 0.03 0.05
AACAAAGATATATTTTC KIAAI199 0.03 0.14
CTGCTATGGTCACTGAG NRN1 0.03 0.15
TTCCTGGAAACCTACGG GOLTIA 0.03 0.14
AACCACTGCTACTCCCG ID3 0.02 0.07
GCCTGTTTGGGAGTGCG UGTIA6 0.02 0.23
AGCTCTTGGAGGCACCA NDRG2 0.02 0.21
TAGAAGATCTATGGAAA NKD1 0.02 0.09
TGAGAGGAGATGGACCC NDUFB5 0.02 0.20
CGTTCCTGCGGACGATC ID1 0.01 0.02
TACAAAATCGATTGGCT IGF2 0.01 0.01
Expression levels were determined by quantitative real-time PCR, and the ratio of node-positive to
node-negative tumors was calculated. Tag expression levels of zero were converted to 0.5 to com-
pute expression ratios.
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we observed a dramatic increase in epithelial fibronectin in node-
positive lesions (Figure 4).
We sought to determine whether inappropriate fibronectin ex-
pression by tumor epithelial cells would cause in vitro effects consis-
tent with lymph node metastasis such as enhancing cell migration
or improving cell survival. To test this hypothesis, we cloned a
full-length cDNA encoding the adult isoform of the FN1 transcript
into pIRES-Neo3, generated stable subclones of SW480 colorec-
tal cancer cells that overexpress the FN1 mRNA and protein rel-
ative to wild-type SW480 cells (Figure 5, A and B). We performed
Boyden chamber migration and Matrigel invasion assays in the
absence and presence of a cyclic RGD-containing peptide. The
FN1-overexpressing clones demonstrated a marked increased ability
to migrate through empty Boyden chambers and invade through
Matrigel barriers in vitro (Figure 6, A and B). This property was
completely abolished by the inclusion of 4.5 μM cyclic RGDf V
peptides into the culture medium. These results demonstrate that
increased fibronectin expression by tumor epithelial cells can cause
enhanced migration and invasion and suggest that targeting a
specific subpopulation of colorectal cancer patients with RGD
peptide–based therapeutics could be more successful than treating
unselected patients.
Discussion
It is estimated that 149,000 cases of colorectal cancer will be di-
agnosed in the United States in 2008 and that 60,000 of these tu-
mors will be detected before regional lymph node involvement [1].
The 5-year survival rate for node-negative colorectal cancer is at best
90%. This means that approximately 6000 people will experience
relapse from early-stage disease. It is possible that at least some of
these individuals were understaged because of occult node-positive
cancer and were therefore undertreated. Adjuvant chemotherapy
can decrease the chances of recurrence for node-negative patients
[18]; however, effective methods of identifying the node-negative pa-
tients who are at highest risk are needed. Applying our seven-gene
classifier to node-negative patients may represent a successful strategy
for identifying these patients. Because gene expression alterations are
caused by gene mutations, it will be important to evaluate the per-
formance of this classifier in the context of somatic mutations to
RAS, RAF, and CSMD1 [19].
The FN1 gene is not expressed by normal colonic epithelial cells
but is overexpressed by the myofibroblasts and epithelial cells of some
colorectal adenocarcinomas [20]. FN1 expression is downregulated as
colon epithelial cells differentiate, suggesting that reexpression in
adenocarcinoma is indicative of epithelial-to-mesenchymal transition
[21]. FN1 expression is associated with poor outcome in other cancers
including melanoma [16], ovarian and breast cancer [22,23], and lym-
phoma [24]. It has also been shown that tumor cell fibronectin pro-
duction is necessary for tumor cell migration in vitro [25]. It is possible
that the progression of colorectal cancer from node-negative to node-
positive disease may be facilitated in part by FN1 deregulation and
subsequent enhanced tumor cell migration.
Figure 3. FN1 (A) and PITX2 (B) mRNA expressions in the epithelial cells of 23 colon cancer specimens. Probability of node-positive
diagnosis based on LR classifier (C) and ROC analysis (D). Cutoff values associated with 20% FPRs for the multigene classifier produced
optimal separation between node-negative and node-positive tumors.
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The mechanism by which FN1 is increased during colorectal can-
cer progression may involve stepwise broadening of WNT signaling.
The WNT pathway is activated by mutations in adenomatous poly-
posis coli or β-catenin and is an initiating event in colorectal tumor
formation leading to enhanced β-catenin/transcription factor 4 tran-
scription [26]. However, these events alone are not sufficient to acti-
vate epithelial FN1 expression. Rather, FN1 expression develops later
in a subset of intestinal tumors, which suggests that secondary genetic
events are necessary to cause an epithelial-to-mesenchymal transition
[27]. WNT signaling is able to induce FN1 expression in fibroblasts
through the action of β-catenin/lymphoid enhancer-binding factor 1
(LEF1) complexes. Normal epithelial cells and early colorectal tumors
lack LEF1 and, therefore, do not express FN1 [28]. SW480 colon
cancer cells contain activating mutations in β-catenin, express tran-
scription factor 4, and, therefore, show high levels of activity of reporter
constructs containing TCF binding sites [29]. SW480 cells are unable
to transactivate FN1 unless exogenous LEF1 is added [28]. Interestingly,
the LEF1 gene is itself transactivated by β-catenin/LEF1/PITX2 com-
plexes [30,31]. We found PITX2 to be increased in expression only in
node-positive colorectal tumors, which is consistent with the idea that
FN1 and other LEF1-dependent WNT targets could be increased dur-
ing disease progression by elevated PITX2.
Gene expression profiling has resulted in the discovery of mark-
ers of early and late colorectal cancer progression [32–35] as well
as good and poor clinical outcome [36]. Genes that contribute to
the underlying mechanism represent attractive targets for diagnostic
and therapeutic purposes. We believe our results indicate that FN1
up-regulation is an important step in the transition from lymph
node–negative to lymph node–positive colorectal cancer. Tumor ep-
ithelial cells that have acquired elevated levels of FN1 migrate more
efficiently and may escape anoikis by propagating survival signals
through integrin receptors [37]. This is but one possible mechanism
by which tumor cells metastasize to distant organs. Other possible
mechanisms, such as inactivating mutations in anoikis pathway
genes, may explain lymph node metastases in tumors that do not up-
regulate FN1 [38]. Because node-negative colon cancers that display
Figure 5. FN1 mRNA (A) and protein (B) expressions in SW480 colo-
rectal cancer cells transfected with pIRES-Neo3-FN1 or an empty
vector control.
Figure 4. (A) Colorectal tumors 30449 (node-negative) and (B) 29203 (node-positive). Nuclei are shown in blue, epithelial cells are shown
in green, and fibronectin is shown in red. The lower right quadrant is an overlay of Fibronectin and BerEP4 staining.
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elevated FN1 and PITX2 may be at high risk for recurrence, future
studies must focus on determining the rates of relapse among large
numbers of these types of patients. Finally, these results suggest that
antagonists of fibronectin-integrin interaction, particularly those that
do not activate downstream survival signals, may be effective agents
for the treatment of colorectal cancers with increased expression of
fibronectin. Cyclic RGD peptides that target fibronectin-integrin in-
teraction have been tested in preclinical models of nonmetastatic, in-
vasive colon cancer and have shown some positive effects [39]. It is
possible that preselecting colon cancer patients for elevated FN1 ex-
pression will result in significant performance gains for cyclic RGD
peptides and related compounds.
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Table W1. Colorectal Tumors Used.
Sample No. Sex Race Age at Diagnosis (years) Nodes Examined Nodes Positive T N M Sample Type
18964 Male AA 83 16 0 3 0 0 SAGE
11330 Female AA 72 10 0 2 0 0 Validation
15095 Male UNK 67 17 0 3 0 0 Validation
16377 Male CA 69 37 0 3 0 0 Validation
18091 Male CA 83 28 0 3 0 0 Validation
23662 Male CA 63 5 0 2 0 0 Validation
29112 Female CA 84 15 0 3 0 0 Validation
30232 Male CA 74 26 0 2 0 0 Validation
30449 Male CA 68 15 0 3 0 0 Validation
40102 Female CA 81 15 0 3 0 0 Validation
40415 Male CA 19 17 0 2 0 0 Validation
29271 Female CA 56 26 2 3 1 1 SAGE
10028 Male CA 53 29 7 3 2 1 Validation
10863 Female AA 55 11 5 3 2 0 Validation
11945 Female CA 51 14 9 X 2 X Validation
12188 Female AA 46 20 4 3 2 0 Validation
14276 Male AA 55 37 2 3 1 0 Validation
30936 Female CA 77 30 1 2 1 0 Validation
29137 Female CA 72 2 1 4 2 1 Validation
29152 Male CA 56 29 12 3 2 0 Validation
29203 Female AA 65 58 3 3 1 0 Validation
29259 Female CA 67 32 3 2 1 0 Validation
29292 Male CA 54 15 1 3 1 0 Validation
3357 Male CA 57 13 8 3 2 1 Validation
40131 Female CA 63 20 1 3 1 0 Validation
Tumor nos. 18964 and 29271 were used for SAGE; the remaining tumors were used for validation studies.
AA indicates African American; CA, Caucasian American; UNK, unknown.
Figure W1. FLJ22104 (A), RPL39 (B), EIF1AX (C), AP3S1 (D), and NDUFA8 (E) mRNA expressions in the epithelial cells of 23 colon can-
cer specimens.
